A randomized crossover study showed that the MiniMed 780G insulin delivery system achieves similar glycemic control whether using the Simplera Sync™ or Abbott's Instinct sensor. This confirms that the SmartGuard™ algorithm is the key factor in managing blood sugar levels, not the sensor itself. The study involved 24 adults with type 1 diabetes using each sensor for six weeks, with results exceeding international glycemic targets and no serious adverse events reported. Real-world data from over 20,000 users further supports the algorithm's central role, giving users flexibility to choose sensors that best fit their lifestyle while maintaining effective diabetes management.
Law Offices of Howard G. Smith reminds investors of upcoming deadlines to file lead plaintiff motions in securities fraud class actions involving Badger Meter, PicS N.V., Verra Mobility, and Grail, Inc. The lawsuits allege these companies made mislea...
Assembli Events & Production is creating the Big Ten Conference's first fan activation at Fanatics Fest NYC, held July 16-19, 2026. This event marks the Big Ten as the first collegiate conference to join the premier sports fan festival, showcasing tr...
State Street posted strong Q2 results with earnings per share of $3.65, beating estimates and up from $2.53 last year. Quarterly revenue reached $4.05 billion, driven by a 17.2% rise in fee revenues and 18% growth in net interest income. Assets under...
U.S. farmers face high and unstable fertilizer prices due to global shipping disruptions, with nearly 70% unable to afford needed fertilizer this season. Denali Water Solutions provides a natural, low-cost fertilizer alternative made from recycled or...
Denodo Technologies released Platform 9.5, improving its AI data layer by providing trusted, governed enterprise context for AI, analytics, and data sharing. Key features include an expanded enterprise knowledge graph, metric views for consistent bus...
